Viroclinics Biosciences setting up Chinese joint venture

To provide better clinical laboratory services to our Chinese and other Asian customers, Viroclinics Biosciences is in negotiations with financial and strategic partners in China.

This content was submitted directly to this website by the supplier.

Additionally Viroclinics will be a silver sponsor and exhibitor at the World Vaccine Congress Asia, which will take place from June 17th to 20th at the Grand Copthorne Waterfront Hotel in Singapore.

World Vaccine Congress Asia 2013
Asia's largest  vaccine event brings together all the major vaccine stakeholders, including pharmaceutical and biotech firms, NGOs, research institutes, regulators and CDCs to discuss the latest industry trends, business strategies and scientific developments in the global and Asian vaccine markets. Besides that, this Terrapin organized event it is co-located with the Asia largest Antibody Congress and commercially-focused orphan drug event.

“We hope to meet a lot of existing and new relations at the World Vaccine Congress Asia 2013,” said Bob van Gemen, CEO of Viroclinics Biosciences, “and discuss the possibilities for partnering and delivering our high quality laboratory service in clinical studies".

A consultative approach to drug and vaccine development
Viroclinics Biosciences B.V. is a preclinical service and clinical laboratory service company with a consultative approach. The close collaboration with the renowned Viroscience Lab of the Erasmus MC in Rotterdam allows the company to support customers with the best virological knowledge available. The company is frontrunner to improve human and animal health by serving the biopharmaceutical community with expert advice and best in class service for (pre)clinical drug development of antivirals, vaccines and additional treatments.  All projects are performed in compliance with established international guidelines under an ISO 15189 accredited quality system.

More in Home